Efectividad de bortezomib y dexametasona en el tratamiento de mieloma m迆ltiple refractario: estudio retrospectivo de una serie de casos consecutivos

作者：Khosravi Shahi; P; Sabin Dominguez; P; Encinas Garcia; S; Izarzugaza Peron; Y; Perez Manga; G

来源：Anales de Medicina Interna, 2008.

DOI：10.4321/S0212-71992008000200005

• bortezomib
• dexamethasone
• progression-free survival
• myeloma
• response rate.

introduction: multiple myeloma (mm) is a plasm-cell neoplasm, that is characterized by a monoclonal protein in the serum or urine. bortezomib is an efficacy drug for the second line treatment of mm. patients and method: we conducted a retrospective study of 21 consecutive cases with refractory mm treated with bortezomib and dexame-thasone as second line therapy, with the objective of analyzing the overall response rate (primary end point), the progression-free survival (pfs), the overall survival (os), the duration of response (dr) and toxicity profile (second end points). results: in our study we found an overall response rate of 70%. with a median follow-up of 15 months, we had a median pfs of 12 months (95% ci: 2-21 months), with a median os of 17 months (95% ci: 2-32 months), and a median dr of 9 months (95% ci: 5-13 months). fourty-seven percent of patients had neuropathy, the 33% thrombocytopenia, 13.33% anemia and 26.66% diarrhea. conclusions: the combination of bortezomib and dexamethasone is an effective and safe treatment in second line of refractory mm, with a manageable toxicity.